Title: Theranostic approach: The present and the future

Biography:

Charl Rafael Macedo da Silva received the MD, PhD in Medicine from OPORTO Medical University. Director of the Nuclear Medicine Department, Health Service of the Autonomous Region of Madeira, E.P.E. (SESARAM, E.P.E.), Madeira, Portugal, Responsible for the construction and licensing of the Nuclear Medicine Unit of SESARAM, EPE, between January 2, 20 and April 4, 205 - Installation financed by the Genhymape Project belonging to the Research Nucleus of Cardiology of SESARAM, EPE, financed 85% the EU. He is the Directorate General of Health, Ministry of Health, Portugal; *Coordinator of Public Unit of Nuclear Medicine - SESARAM, E.PE. - Funchal, Portugal. He has presented 80+ oral and poster presentations in International, National and Regional Nuclear Medicine Meetings.

rafaelmacedo.mednuclear@gmail.com

Abstract

Personalized medicine is having an increasingly wide-ranging discussion today. For this, nuclear medicine has played its fundamental role in the diagnosis and decision in the treatment of diverse oncological pathologies, in a perspective increasingly focused on the individual. Taking into account that we are witnessing an increase in cancer prevalence on a global scale, we must also focus on an economistic view, both due to the costs involved in all procedures currently underway for the entire follow-up process, without prejudice to the quality of the diagnosis / treatment. Thus, the purpose of this presentation is based on the description of the means of diagnosis and therapy currently performed by the personalized nuclear / molecular medicine and on the signaling of possible pathways to follow, with the most current diagnostic means such as pet / MRI, as form of diagnostic evaluation and assessment of response to therapy, integrated. What if we could move to the investment of new positron-emitting radiopharmaceuticals with paramagnetic properties ideal for MRI imaging? Simultaneous acquisition may provide new perspectives for imaging diagnosis, a possible better evaluation of response to therapy with cost reduction and less exposure to ionizing radiation. This presentation aims to promote the discussion about the development of this possibility of functional / molecular and structural / macroscopic assessment of oncological cases in an integrated and personalized perspective. What is the current state of the art about these possible new radiopharmaceuticals and what is the perspective of their use in the short and medium term?